Last reviewed · How we verify

Albutrepenonacog Alfa 1 UNT [IDELVION]

National Taiwan University Hospital · FDA-approved active Small molecule

Albutrepenonacog Alfa 1 UNT [IDELVION] is a Recombinant coagulation factor (Factor IX fusion protein) Small molecule drug developed by National Taiwan University Hospital. It is currently FDA-approved for Hemophilia B (Factor IX deficiency) — routine prophylaxis and on-demand treatment of bleeding episodes.

Albutrepenonacog alfa is a recombinant fusion protein that replaces deficient Factor IX (Christmas factor) to restore blood coagulation in hemophilia B patients.

Albutrepenonacog alfa is a recombinant fusion protein that replaces deficient Factor IX (Christmas factor) to restore blood coagulation in hemophilia B patients. Used for Hemophilia B (Factor IX deficiency) — routine prophylaxis and on-demand treatment of bleeding episodes.

At a glance

Generic nameAlbutrepenonacog Alfa 1 UNT [IDELVION]
SponsorNational Taiwan University Hospital
Drug classRecombinant coagulation factor (Factor IX fusion protein)
TargetFactor IX (coagulation factor IX)
ModalitySmall molecule
Therapeutic areaHematology
PhaseFDA-approved

Mechanism of action

This drug is a genetically engineered Factor IX variant fused to albumin, which extends its half-life and improves pharmacokinetics compared to standard Factor IX concentrates. It restores the intrinsic coagulation pathway by providing the missing clotting factor, enabling normal thrombin generation and fibrin clot formation in patients with hemophilia B (Factor IX deficiency).

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Albutrepenonacog Alfa 1 UNT [IDELVION]

What is Albutrepenonacog Alfa 1 UNT [IDELVION]?

Albutrepenonacog Alfa 1 UNT [IDELVION] is a Recombinant coagulation factor (Factor IX fusion protein) drug developed by National Taiwan University Hospital, indicated for Hemophilia B (Factor IX deficiency) — routine prophylaxis and on-demand treatment of bleeding episodes.

How does Albutrepenonacog Alfa 1 UNT [IDELVION] work?

Albutrepenonacog alfa is a recombinant fusion protein that replaces deficient Factor IX (Christmas factor) to restore blood coagulation in hemophilia B patients.

What is Albutrepenonacog Alfa 1 UNT [IDELVION] used for?

Albutrepenonacog Alfa 1 UNT [IDELVION] is indicated for Hemophilia B (Factor IX deficiency) — routine prophylaxis and on-demand treatment of bleeding episodes.

Who makes Albutrepenonacog Alfa 1 UNT [IDELVION]?

Albutrepenonacog Alfa 1 UNT [IDELVION] is developed and marketed by National Taiwan University Hospital (see full National Taiwan University Hospital pipeline at /company/national-taiwan-university-hospital).

What drug class is Albutrepenonacog Alfa 1 UNT [IDELVION] in?

Albutrepenonacog Alfa 1 UNT [IDELVION] belongs to the Recombinant coagulation factor (Factor IX fusion protein) class. See all Recombinant coagulation factor (Factor IX fusion protein) drugs at /class/recombinant-coagulation-factor-factor-ix-fusion-protein.

What development phase is Albutrepenonacog Alfa 1 UNT [IDELVION] in?

Albutrepenonacog Alfa 1 UNT [IDELVION] is FDA-approved (marketed).

What are the side effects of Albutrepenonacog Alfa 1 UNT [IDELVION]?

Common side effects of Albutrepenonacog Alfa 1 UNT [IDELVION] include Injection site reactions, Headache, Thrombotic events (rare), Inhibitor development (alloimmunization).

What does Albutrepenonacog Alfa 1 UNT [IDELVION] target?

Albutrepenonacog Alfa 1 UNT [IDELVION] targets Factor IX (coagulation factor IX) and is a Recombinant coagulation factor (Factor IX fusion protein).

Related